Down 12%, Should You Buy the Dip on Eli Lilly?

Eli Lilly's stock, driven by its weight loss drugs Zepbound and Mounjaro which generated over $16 billion in revenue last year, has pulled back 12% since March, presenting a potential buying opportunity. The company is developing orforglipron, a weight loss pill, and retatrutide, a triple-hormone drug, to further capitalize on the expanding weight loss market projected to reach nearly $100 billion in five years, despite potential headwinds such as reimbursement challenges and pricing pressures.

Analysis

Eli Lilly (LLY) has demonstrated significant growth, primarily fueled by its successful weight loss drug portfolio, Zepbound and Mounjaro, which collectively generated over $16 billion in revenue in the last year and contributed to a stock appreciation of over 170% in three years. Despite this strong performance, the stock recently experienced a 12% pullback from its March high, bringing its forward earnings multiple down to 37x from nearly 43x. This valuation, while still premium and likened to a tech stock, is presented as potentially more attractive. Future growth is anticipated from the expanding weight loss drug market, projected to reach nearly $100 billion in approximately five years from its current $28 billion. Lilly's pipeline includes promising candidates such as orforglipron, an oral weight loss drug aiming for regulatory approval by year-end, and retatrutide, a phase 3 candidate acting on three hormonal pathways, suggesting potential for enhanced efficacy. The company is bolstering its manufacturing capabilities with over $50 billion invested in the U.S. over the past five years. However, potential headwinds include reimbursement challenges from health plans and pricing pressures from competitors, factors that led Goldman Sachs Research to revise its obesity drug market forecast downward to $95 billion by 2030 from $130 billion. Nevertheless, Lilly's leadership in innovation, exemplified by orforglipron's unique pill format, and the inherent revenue stability of a large pharmaceutical company, alongside dividend payments, position it favorably according to the article.

Key Decisions for Investors

• Consider the recent 12% decline in Eli Lilly's stock price from its March peak as a potential entry point for exposure to its leadership in the high-growth obesity drug market.
• Evaluate the current forward P/E of 37x by weighing it against the company's substantial revenue from current blockbusters, its robust drug pipeline featuring orforglipron and retatrutide, and the projected expansion of the weight loss market.
• Monitor potential risks such as evolving reimbursement policies from healthcare payers and increasing competition, which could introduce pricing pressures and impact market growth forecasts.
• Recognize that Eli Lilly offers a combination of significant growth prospects, typically associated with higher valuation multiples, alongside the defensive characteristics and dividend income of an established pharmaceutical entity.